Two large randomized trials have advanced our knowledge of myeloma care. The first study reported that autologous stem-cell transplantation remains the frontline therapy for transplant-eligible patients with multiple myeloma in the current era of novel agents. Together, this study and the second large trial in transplant-ineligible patients demonstrate the value of maintenance treatment with continuous lenalidomide.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barlogie, B. et al. Curing myeloma at last: defining criteria and providing the evidence. Blood http://dx.doi.org/10.1182/blood-2014-07-552059.
Child, J. A. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875–1883 (2003).
Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7–15 (2012).
Rajkumar, S. V., Gahrton, G. & Bergsagel, L. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118, 3205–3211 (2011).
van Rhee, F., Giralt, S. & Barlogie, B. The future of autologous stem cell transplantation in myeloma. Blood 124, 328–333 (2014).
Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N. Engl. J. Med. 317, 895–905 (2014).
Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).
Fritz, E. & Ludwig, H. Interferon-α treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann. Oncol. 11, 1427–1436 (2000).
Lonial, S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953–1959 (2012).
Plesner, T. et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma [abstract]. Blood 122, a1986 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Morgan, G., van Rhee, F. Optimizing the treatment of multiple myeloma. Nat Rev Clin Oncol 11, 686–688 (2014). https://doi.org/10.1038/nrclinonc.2014.185
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.185
